Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NA...
NEW YORK, NY / ACCESSWIRE / April 9, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional informat...
2024-04-06 09:50:00 ET Verve Therapeutics (NASDAQ: VERV) saw its shares crater by 36% on April 2 when it reported that a serious mishap had occurred in one of its clinical trials. Understandably, investors may now question whether the gene-editing biotech has a shot at recovering, o...
2024-04-05 14:32:16 ET More on Markets AllianceBernstein spotlights demand shifts in the EV industry We're seeing new money come into Bitcoin – TD Securities Treasury yields continue to climb, see what SA analysts have to say AllianceBernstein warns of...
2024-04-03 14:15:00 ET Summary Verve is targeting patients with genetically-driven high cholesterol levels, and they are making a single A-to-G change in the gene for the PCSK9 protein. Verve announced their results yesterday, and it's a glass-half-full story. They say that they'v...
2024-04-03 11:57:45 ET Summary Enrollment paused in the Verve Therapeutics' phase 1b heart-1 study, using VERVE-101 for the treatment of patients with heterozygous familial hypercholesterolemia after a Grade 3 adverse event. Despite VERVE-101 setback, the ability to move forward w...
2024-04-03 09:30:03 ET BMO Capital analyst issues OUTPERFORM recommendation for VERV on April 3, 2024 07:43AM ET. The previous analyst recommendation was Outperform. VERV was trading at $8.32 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
A look at the top 10 most actives in the United States Trio Petroleum Corp. (TPET) rose 43.8% to $0.1485 on volume of 202,621,744 shares Nikola Corporation (NKLA) fell 5.5% to $0.9736 on volume of 187,304,976 shares C3is Inc. (CISS) rose 13.3% to $0.0409 on volume of 136,767,990 shares ...
2024-04-02 14:30:01 ET RBC Capital analyst issues OUTPERFORM recommendation for VERV on April 2, 2024 12:59PM ET. The previous analyst recommendation was Outperform. VERV was trading at $8.215 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-04-02 13:01:35 ET Read the full article on Seeking Alpha For further details see: XTIA, TPET and GSIT among mid-day movers
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
2024-05-14 21:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Recei...
First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for collaboration on an in vivo gene editing program targeting lipoprotein(a) (Lp(a)) ...